Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind 4-Week Study to Evaluate the Impact of AXS-05 on Smoking Behavior

Next Previous
Trial Profile

A Randomized, Double-Blind 4-Week Study to Evaluate the Impact of AXS-05 on Smoking Behavior

Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Jan 2019

At a glance

  • Drugs Bupropion/dextromethorphan (Primary) ; Bupropion
  • Indications Smoking withdrawal
  • Focus Therapeutic Use

    • Most Recent Events

    • 11 Jan 2019 Planned End Date changed from 21 Jan 2019 to 31 May 2019.
    • 11 Jan 2019 Planned primary completion date changed from 31 Dec 2018 to 31 Mar 2019.
    • 27 Dec 2018 According to an Axsome Therapeutics media release, top-line results are anticipated in the first quarter of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top